B&
Burrill & Company
Private EquityActiveBurrill & Company is a venture capital and private equity firm that invests in life sciences, biotechnology, and healthcare companies.
87
Investments
10
Exits
$1.4B
AUM
11.5%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Burrill & Company.
Investment Thesis & Strategy
Burrill & Company invests in various stages of life sciences, biotechnology, and healthcare companies, leveraging its expertise to drive growth and innovation within these sectors.
Notable Exits
CompanyTypeYearValue / Acquirer
DendreonAcquisition2015$480M
Ambit BiosciencesAcquisition2014$410M
XencorIPO2013—
Onyx PharmaceuticalsAcquisition2013$10.4B
Theravance BiopharmaIPO2013—
GenentechAcquisition2009$46.8B
MedImmuneAcquisition2007$15.6B
Sirna TherapeuticsAcquisition2006$550M
Ligand PharmaceuticalsIPO1992—
Gilead SciencesIPO1992—
Frequently Asked Questions
Burrill & Company focuses on Series B, Series C+ stage investments.
Related Investors
Spectrum Equity
San Francisco, United States · 107 deals
Foresite Capital
San Francisco, United States · 87 deals
FTV Capital
San Francisco, United States · 78 deals
Francisco Partners
San Francisco, United States · 49 deals
venBio Partners
San Francisco, United States · 48 deals
Serent Capital
San Francisco, United States · 36 deals